Amysulpryd

When ATH:
N05AL05

Pharmacological action.
Antipsychotic.

Application.

Acute and chronic schizophrenic disorders, accompanied by a pronounced positive (delirium, hallucinations, Disorder thinking, and others.) and / or negative (affective dullness, lack of emotion and care of communication and others.) symptoms, incl. for patients with predominantly negative symptoms.

Contraindications.

Hypersensitivity, pheochromocytoma, prolaktinzavisimye tumor (incl. prolactinoma pituitary), mammary cancer, childhood and adolescence (to 15 years).

Pregnancy and breast-feeding.

Use in pregnancy is not recommended, except, when the effect of therapy outweighs the potential risk to the fetus (adequate and well-controlled studies in pregnant women have not performed). Contraindicated during breastfeeding (unknown, whether amisulpride gets into breast milk).

Side effects.

From the nervous system and sensory organs: insomnia, anxiety, excitation, drowsiness, extrapyramidal disorder, pozdnyaya dyskinesia, seizures, neuroleptic malignant syndrome.

From the digestive tract: constipation, nausea, vomiting, dry mouth.

Other: hyperprolactinemia (incl. breast pain, amenorrhea, galactorrhea, gynecomastia, sexual dysfunction, impotence), weight gain, gipotenziya, bradycardia, elongation QT interval on an electrocardiogram, increased liver transaminases, allergic reactions.

Cooperation.

It is an antagonist of levodopa. When combined with antihypertensives, certain antihistamines and deprimiruyuschie means (analgesics, general anesthetics, trankvilizatorы, alcohol and others.) requires caution.

Dosing and Administration.

Inside. When producing states (including acute psychotic episode) -400-800 mg/day (the maximum daily dose 1200 mg), negative symptoms — 50-300 mg/day. The duration of treatment and the maintenance dose determined individually. At doses, exceeding 400 mg / day, amisulpride should be used in 2 admission.

Precautions.

With caution is prescribed for kidney failure, epilepsy, parkinsonizme, elderly patients; during the drivers of vehicles and people, skills relate to the high concentration of attention. All the treatment is excluded alcohol intake.

Cooperation

Active substanceDescription of interaction
AlprazolamFMR: synergism. Strengthens (mutually) deprimiruyuschie effect.
AmiodaroneFMR. Increases (mutually) the risk of ventricular arrhythmias such as "pirouette"; concomitant use is contraindicated.
BromdigidrohlorfenilbenzodiazepinFMR: synergism. Strengthens (mutually) deprimiruyuschie effect.
MetamizoleFMR: synergism. Against the background enhances the effect of amisulpride.
TioridazinFMR. Increases (mutually) the risk of ventricular arrhythmias such as "pirouette"; concomitant use is contraindicated.
QuinidineFMR. Increases (mutually) the risk of ventricular arrhythmias such as "pirouette"; concomitant use is contraindicated.
EthanolFMR: synergism. Against the backdrop of intensified amisulpride deprimiruyuschie effect; at the time of treatment should abandon spirits.

Back to top button